Larazotide Acetate vs Thymosin Alpha-1
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
Larazotide AcetateImmune SupportAnti-Aging & Longevity
Thymosin Alpha-1- Summary
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
- Half-Life
- Local gut action; minimal systemic exposure
- 2–3 hours
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 0.5-2 mg
- 0.8–1.6 mg
- Frequency
- 3x daily
- Twice weekly
- Key Benefits
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Enhances T-cell and NK cell activity
- Supports recovery from viral and bacterial infections
- May reduce inflammation systemically
- Supports healthy aging and immune resilience
- Improves vaccine response
- Supports liver health
- May help with chronic fatigue syndrome and post-viral conditions
- Approved in multiple countries for hepatitis B and C treatment
- Side Effects
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Injection site irritation
- Mild flu-like symptoms initially (immune activation)
- Fatigue (rare)
- Stacks With
- —
- —